Critical Biologics Corporation

About:

Critical Biologics Corp., a development stage biotechnology company, develops and commercializes diagnostics and therapeutics that predict

Website: http://www.criticalbiologics.com

Description:

Critical Biologics Corp., a development stage biotechnology company, develops and commercializes diagnostics and therapeutics that predict and regulate inflammatory responses to life-threatening diseases. The company focuses on a theranostic approach to treat critical care patients with low plasma gelsolin (pGSN) levels at high risk of life-threatening complications. Its products include SolinDx, an ELISA assay kit used for the measurement of pGSN in human plasma samples; ActinDx, an ELISA assay kit used for the quantitative measurement of the amount of circulating actin in serum; and Solinex, an investigational drug. The company has a strategic partnership wit QSV Biologics, Ltd. to manufacture pharmaceutical recombinant human pGSN. Critical Biologics Corp. was founded in 2004 and is based in Cambridge, Massachusetts with an additional office in Hunterdon County, New Jersey.

Total Funding Amount:

$500000

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2004-01-01

Founders:

James W. Fordyce

Number of Employees:

1-10

Last Funding Date:

2009-07-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai